An injectable, dual-crosslinked polypeptide hydrogel encapsulating resiquimod-loaded nanoparticles as a long-lasting immunoprotective tumor vaccine

Jiaxuan Yang a b , Yijun Wu a b , Yunan Yuan a b , Fujiang Li a b , Ruonan Huang a b , Qian Cheng a b , Yan Rong a , Xuesi Chen a b , Chaoliang He

Journal of Controlled Release. 2026 Jun 10 .

Influencing factors：11.5

Spliceosomal mutation drives melanoma tumorigenesis via lineage-specific RAS activation

Ruixin Jiang 1,2,†, Peiqi Xing 3,4,*,†, Jindou Xie 3,4,5, Gang Bai 2, Yuzhu Zhang 2, Pengcong Hou 2, Hao Luo 2, Yanni Ma 2, Ruixin Liu 2, Yang Zheng 6, Xiangyu Chen 7, Bin Jiang 1, Jing Huang 2, Yanjie Zhang 1,2, A Hunter Shain 8,9, Ming Lei 2,10, Robert L Judson-Torres 11,12,13, Jing Ye 14, Zhaoqi Liu 3,4,5,*, Hanlin Zeng

Sci Adv. 2026 May 1 .

Influencing factors：12.5

Octopus-inspired engineered bacteria with a plug-and-play surface display system achieves enhanced tumor-specific colonization and antitumor immunity

Le-Yang Wu a,b,1,⁎, Jia-Hui Qiu a,1, Xin-Yue Qiao a, Lin Li a, Li-Yuan Qiao a, Chen-Yang Li a, Ying Sun a, Shu-Hui Zhang a, Zeng-Zheng Du a, Xiao-Yao Chang a, Cheng Cheng c, Bo-Hao Wang a, Yi-Han Xiao a, Lin Lin d,⁎, Zi-Chun Hua

Mil Med Res. 2026 Apr 27 .

Influencing factors：22.9

FOXC2 represses NFAT1-dependent transcription through a DNA-facilitated protein-protein interaction

Xiaojuan Chen 1, Sipeng Wu 2, Sitong Yue 3, Lin Zhang 4, Xueru Liu 5, Shuyan Dai 6,7, Jun Li 8, Huajun Zhang 9,10, Hudie Wei 11, Ming Guo 12, Lingzhi Qu 13, Lin Chen 14, Yalan Deng 15,16,✉, Yongheng Chen 17,✉

Nucleic Acids Res. 2026 Apr 23 .

Influencing factors：13.1

A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis

Dingyu Wu 1,2, Lei Duan 3, Di Tan 4, Xinyi Hua 1,2, Anping Liang 1,2, Ruiping Huai 1,2, Shanshan Qi 1,2, Zhixian Shang 1, Shijie Jia 1, Hui Qi 1, Xinrong Liu 1, Jieling Zhao 1, Yuhong Jiang 1, Rui Tan 1,✉, Canquan Mao

Theranostics. 2026 Apr 23 .

Influencing factors：13.3

Proteomic profiling and molecular reclassification of high-grade serous ovarian cancer identifies prognostic subtypes and immunotherapy biomarkers

Mengyan Tu a,b,e, Sangsang Tang a,b,e, Qiao Zhang c,e, Tianchen Guo a,b,e, Yixuan Cen a,b, Xiaomeng Xu c, Shenglong Wu a,b, Xin Chen a,b, Weiguo Lu a,b,d,∗, Chen Ding c,∗∗, Junfen Xu

eBioMedicine. 2026 Apr 18 .

Influencing factors：10.8